Bioxytran, Inc. (BIXT) Stock

About Bioxytran, Inc.

Bioxytran, Inc. is a pharmaceutical firm operating in the clinical development phase, dedicated to creating, producing, and marketing medicinal treatments for oxygen deficiency (hypoxia) in people. Its primary drug under development, BXT-25, is a small, oxygen-transporting molecule crafted from bovine hemoglobin, stabilized by a co-polymer. This compound is intended for tackling oxygen deprivation in the brain caused by strokes, as well as addressing wound hypoxia to avert tissue death and encourage recovery. Additionally, Bioxytran is advancing ProLectin-Rx, a pectin-derived polysaccharide. This substance functions by attaching to and inhibiting galectin-1, a specific galectin, to treat mild to moderate instances of Covid-19. Established in 2008, the company maintains its main office in Newton, Massachusetts.

Bioxytran, Inc. is headquartered in US.

Bioxytran, Inc. (BIXT) stock trades at $0.02 with a market capitalization of $2.37M. The stock is valued at a price-to-earnings (P/E) ratio of -0.91, price-to-book of -0.61, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.02 and $0.10, and currently trades 80.0% below its 52-week high.

On profitability, Bioxytran, Inc. generates a return on equity (ROE) of 90.64% — well above the market average, a sign of a high-quality business, return on capital employed of 74.45%, an operating margin of 0.00%, a net profit margin of 0.00%.

Official website: www.bioxytraninc.com